The stimulation of CD8+ T cells by dendritic cells pulsed with polyketal microparticles containing ion-paired protein antigen and poly(inosinic acid)–poly(cytidylic acid)
Source abstract
Abstract
New adjuvants and delivery strategies are needed to optimize the ability of protein-based vaccines to elicit CD8(+) T cell responses. We have developed a model vaccine formulation containing ovalbumin (OVA) and the double-stranded RNA analog poly(inosinic acid)-poly(cytidylic acid) (poly(I:C)), a TLR3 agonist. OVA and poly(I:C) were each ion-paired to cetyltrimethylammonium bromide (CTAB) to produce hydrophobic complexes, which were co-encapsulated in pH-sensitive polyketal (PK3) microparticles (1-3 microm) using a single emulsion method. Loading levels ranged from 13.6 to 18.8 microg/mg OVA and 4.8 to 10.3 microg/mg poly(I:C). Murine splenic dendritic cells (DCs) pulsed with PK3-OVA-poly(I:C) microparticles, at antigen doses of 0.01 and 0.1 microg/mL, induced a higher percentage of IFNgamma-producing CD8(+) T cells than DCs treated with PK3-OVA particles or soluble OVA/poly(I:C). A higher antigen dose (1 microg/mL) was less effective, which can be attributed to CTAB toxicity. At the lowest antigen dose (0.01 microg/mL), PK3-OVA-poly(I:C) microparticles also enhanced TNF-alpha and IL-2 production in CD8(+) T cells. These data demonstrate the potential of polyketal microparticles in formulating effective CD8(+) T cell-inducing vaccines comprising protein antigens and dsRNA adjuvants.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Immunotherapy and Immune Responses · RNA Interference and Gene Delivery · Immune Response and Inflammation
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (48)
Show source-provided references
1. Triggering TLR signaling in vaccination10.1016/j.it.2005.11.005 ↗
2. T-cell quality in memory and protection: implications for vaccine design10.1038/nri2274 ↗
3. Targeting the innate immune response with improved vaccine adjuvants10.1038/nm1210 ↗
4. Vaccine protocols for enhanced immunogenicity of exogenous antigens10.1016/j.ijmm.2007.08.004 ↗
5. Toll-like receptor control of the adaptive immune responses10.1038/ni1112 ↗
6. Modulating vaccine responses with dendritic cells and Toll-like receptors10.1111/j.0105-2896.2004.00144.x ↗
7. Variegation of the immune response with dendritic cells and pathogen recognition receptors10.4049/jimmunol.174.5.2457 ↗
8. A subset of toll-like receptor ligands induces cross-presentation by bone marrow-derived dendritic cells10.4049/jimmunol.170.8.4102 ↗
9. Toll-like receptor 3 promotes cross-priming to virus-infected cells10.1038/nature03326 ↗
10. Polyriboinosinic polyribocytidylic acid (poly(I:C)) induces stable maturation of functionally active human dendritic cells10.4049/jimmunol.163.1.57 ↗
11. Recognition of double-stranded RNA and activation of NF-kappa B by Toll-like receptor 310.1038/35099560 ↗
12. Nasal immunization with the mixture of PA63, LF, and a PGA conjugate induced strong antibody responses against all three antigens10.1111/j.1574-695X.2007.00347.x ↗
13. The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine10.1073/pnas.0711976105 ↗
14. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens10.1084/jem.194.6.863 ↗
15. Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells10.1002/1521-4141(200111)31:11<3388::AID-IMMU3388>3.0.CO;2-Q ↗
16. Plasmacytoid dendritic cells, antigen, and CpG-C license human B cells for plasma cell differentiation and immunoglobulin production in the absence of T-cell help10.1182/blood-2003-08-2972 ↗
17. Specialization, kinetics, and repertoire of type 1 interferon responses by human plasmacytoid predendritic cells10.1182/blood-2005-07-2709 ↗
18. Immune system activation and fatigue during treadmill running: role of interferon
19. The sickness behaviour and CNS inflammatory mediator profile induced by systemic challenge of mice with synthetic double-stranded RNA (poly I:C)10.1016/j.bbi.2006.12.007 ↗
20. Prolonged effects of polyriboinosinic:polyribocytidylic acid on spontaneous running wheel activity and brain interferon-alpha mRNA in rats: a model for immunologically induced fatigue10.1016/S0306-4522(03)00365-8 ↗
21. Uptake of poly(d,l-lactic-co-glycolic acid) microspheres by antigen-presenting cells in vivo10.1002/jbm.10019 ↗
22. Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens10.1016/j.addr.2004.09.003 ↗
23. Antigen co-encapsulated with adjuvants efficiently drive protective T cell immunity10.1002/eji.200737169 ↗
24. Analysis of the role of vaccine adjuvants in modulating dendritic cell activation and antigen presentation in vitro10.1016/S0264-410X(02)00531-5 ↗
25. Enhanced antigen-specific primary CD4+ and CD8+ responses by codelivery of ovalbumin and toll-like receptor ligand monophosphoryl lipid A in poly(d,l-lactic-co-glycolic acid) nanoparticles10.1002/jbm.a.31019 ↗
26. Incorporation of CpG oligonucleotide ligand into protein-loaded particle vaccines promotes antigen-specific CD8 T-cell immunity10.1021/bc060165i ↗
27. Toll-dependent selection of microbial antigens for presentation by dendritic cells10.1038/nature04596 ↗
28. Protein stability in controlled-release systems10.1038/71875 ↗
29. The acidic microclimate in poly(lactide-co-glycolide) microspheres stabilizes camptothecins10.1023/A:1018876308346 ↗
30. Microencapsulation of DNA using poly(dl-lactide-co-glycolide): stability issues and release characteristics10.1016/S0168-3659(99)00151-0 ↗
31. Novel approaches in microparticulate PLGA delivery systems encapsulating proteins10.1039/b706939a ↗
32. Polyketal nanoparticles: a new pH-sensitive biodegradable drug delivery vehicle10.1021/bc050176w ↗
33. Polyketal microparticles: a new delivery vehicle for superoxide dismutase10.1021/bc060259s ↗
34. Polyketal copolymers: a new acid-sensitive delivery vehicle for treating acute inflammatory diseases10.1021/bc700442g ↗
35. Thermostabilization of ovalbumin in a developing egg by an alkalinity-regulated, two-step process10.1271/bbb.65.2021 ↗
36. RAG-1-deficient mice have no mature B and T lymphocytes10.1016/0092-8674(92)90030-G ↗
37. T cell receptor antagonist peptides induce positive selection10.1016/0092-8674(94)90169-4 ↗
38. Effector and memory CTL differentiation10.1146/annurev.immunol.25.022106.141548 ↗
39. Enhanced solubility of proteins and peptides in nonpolar solvents through hydrophobic ion-pairing10.1002/bip.360330608 ↗
40. Hydrophobic ion pairing: altering the solubility properties of biomolecules10.1023/A:1011998014474 ↗
41. Biodegradable nanoparticles containing protein-fatty acid complexes for oral delivery of salmon calcitonin10.1002/jps.10573 ↗
42. A potential approach for decreasing the burst effect of protein from PLGA microspheres10.1002/jps.10414 ↗
43. Degradation kinetics of high molecular weight poly(l-lactide) microspheres and release mechanism of lipid:DNA complexes10.1002/jps.20176 ↗
44. Effect of cationic liposome composition on in vitro cytotoxicity and protective effect on carried DNA10.1016/0378-5173(96)04574-7 ↗
45. Cytotoxicity characterization of catanionic vesicles in RAW 264.7 murine macrophage-like cells10.1016/j.colsurfb.2004.12.008 ↗
46. Comparison of two methods of encapsulation of an oligonucleotide into poly(d,l-lactic acid) particles10.1016/S0378-5173(00)00627-X ↗
47. Toll-like receptor ligands modulate dendritic cells to augment cytomegalovirus- and HIV-1-specific T cell responses10.4049/jimmunol.171.8.4320 ↗
48. Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes10.4049/jimmunol.176.12.7335 ↗